News

News Archive

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS)

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS)

FLORENCE, Italy, November 30th, 2022 - The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics...
Lost childhood: a 'tight-knit' network to combat abuse and distress

Lost childhood: a 'tight-knit' network to combat abuse and distress

Rome, December 7th, 2022 – Setting real changes in motion through dialogue among experts in order to tackle the unresolved issues of juvenile distress. This was the topic addressed...
Le Volpi Rosse Menarini continuano la loro avventura in Serie A

Le Volpi Rosse Menarini continuano la loro avventura in Serie A

Page available only in Italian language

QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform

QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform

NEWCASTLE UPON TYNE, UK and FLORENCE, ITALY, 2nd November 2022, QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point-of-Need molecular...
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

NEWTON, Mass. and FLORENCE, Italy,– November 1st, 2022 – Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More